International Clinical Psychopharmacology最新文献_第7页

The impact of efficacy of long-acting injectable antipsychotics on caregivers' burden of patients with schizophrenia. 长效注射抗精神病药物的疗效对精神分裂症患者护理负担的影响。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-02-22 DOI: 10.1097/YIC.0000000000000539

Enrico Capuzzi, Cecilia Quitadamo, Alice Caldiroli, Massimo Clerici, Massimiliano Buoli

引用次数: 0

The effect of early or late initiation of long-acting antipsychotics on the caregiver burden in schizophrenia. 早或晚服用长效抗精神病药物对精神分裂症患者照顾者负担的影响。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2023-11-23 DOI: 10.1097/YIC.0000000000000524

Dilara Çırakman, Ersin Hatice Karslıoğlu, Neşe Burcu Bal, Ali Çayköylü

{"title":"The effect of early or late initiation of long-acting antipsychotics on the caregiver burden in schizophrenia.","authors":"Dilara Çırakman, Ersin Hatice Karslıoğlu, Neşe Burcu Bal, Ali Çayköylü","doi":"10.1097/YIC.0000000000000524","DOIUrl":"10.1097/YIC.0000000000000524","url":null,"abstract":"The effective treatment in the early stages of schizophrenia is of critical importance to improve the prognosis. Schizophrenia affects patients' relatives too. The effects of early or late initiation of long-acting injectable antipsychotics (LAI-APs) on the patient have been shown, yet their effects on the caregiver are still unknown. We aimed to determine how the time of initiation of LAI-APs affects the caregiver burden by comparing the patients who were started on LAI-APs in the first 5 years of diagnosis and those who were started at a later period. Patients were classified as 'early-LAI' and 'late-LAI' according to the time of initiation of a LAI-AP. Their caregivers were also classified as the same way, as 'caregiver-early' and 'caregiver-late' and were compared in terms of caregiver burden. The quality of life, depression, anxiety, and caregiver burden scores of the caregiver-late group were significantly worse. The time of initiation of LAI-APs and the functioning levels of the patients were found to be determinant factors for the caregiver burden. This is the first study to investigate the effects of LAI-AP's initiation time on the caregivers to our knowledge. The use of LAI-APs in the early stages is associated with better outcomes for the caregiver.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"313-322"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Type 2 diabetes mellitus is associated with manic morbidity in elderly patients with mood disorders. 2型糖尿病与老年情绪障碍患者的躁狂发病率有关。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2023-10-21 DOI: 10.1097/YIC.0000000000000515

Francesco Weiss, Giulio Emilio Brancati, Camilla Elefante, Alessandra Petrucci, Teresa Gemmellaro, Lorenzo Lattanzi, Giulio Perugi

{"title":"Type 2 diabetes mellitus is associated with manic morbidity in elderly patients with mood disorders.","authors":"Francesco Weiss, Giulio Emilio Brancati, Camilla Elefante, Alessandra Petrucci, Teresa Gemmellaro, Lorenzo Lattanzi, Giulio Perugi","doi":"10.1097/YIC.0000000000000515","DOIUrl":"10.1097/YIC.0000000000000515","url":null,"abstract":"The association between mood disorders, especially bipolar disorder (BD), and metabolic disorders, is long known. However, to which extent metabolic disorders affect the course of mood disorders in late life is still open to inquiring. To assess the impact of type 2 diabetes mellitus (T2DM) on late-life mood disorders a retrospective chart review was performed. Elderly depressive patients (≥ 65 years) diagnosed with Major Depressive Disorder (N = 57) or BD (N = 43) and followed up for at least 18 months were included and subdivided according to the presence of T2DM comorbidity. Vascular encephalopathy (39.1% vs. 15.6%, P = 0.021) and neurocognitive disorders (21.7% vs. 5.2%, P = 0.028), were more frequently reported in patients with T2DM than in those without. Patients with T2DM showed a greater percentage of follow-up time in manic episodes (r = -0.23, P = 0.020) and a higher rate of manic episode(s) during follow-up (21.7% vs. 5.2%, P = 0.028) than those without. When restricting longitudinal analyses to patients with bipolar spectrum disorders, results were confirmed. In line with the well-known connection between BD and metabolic disorders, our data support an association between T2DM and unfavorable course of illness in the elderly with BD.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"294-304"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41199836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term remission following esketamine nasal spray sessions in a patient with severe and highly treatment-resistant depression: a single-case report. 一名严重且高度耐药的抑郁症患者在使用埃斯卡他敏鼻腔喷雾剂后病情得到长期缓解：单个病例报告。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2023-07-11 DOI: 10.1097/YIC.0000000000000482

Lucas Arrighi, Eloïse Maakaron, Théo Korchia, Christophe Lançon, Raphaëlle Richieri

引用次数: 0

The impact of mild behavioral impairment on the prognosis of geriatric depression: preliminary results. 轻度行为障碍对老年抑郁症预后的影响:初步结果。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2023-11-15 DOI: 10.1097/YIC.0000000000000521

Camilla Elefante, Giulio Emilio Brancati, Gabriele Pistolesi, Salvatore Amadori, Samuele Torrigiani, Filippo Baldacci, Roberto Ceravolo, Zahinoor Ismail, Lorenzo Lattanzi, Giulio Perugi

{"title":"The impact of mild behavioral impairment on the prognosis of geriatric depression: preliminary results.","authors":"Camilla Elefante, Giulio Emilio Brancati, Gabriele Pistolesi, Salvatore Amadori, Samuele Torrigiani, Filippo Baldacci, Roberto Ceravolo, Zahinoor Ismail, Lorenzo Lattanzi, Giulio Perugi","doi":"10.1097/YIC.0000000000000521","DOIUrl":"10.1097/YIC.0000000000000521","url":null,"abstract":"Our study aimed to examine how the presence of Mild Behavioral Impairment (MBI) symptoms influenced the outcome of late-life depression (LLD). Twenty-nine elderly (≥ 60 years) depressive patients, including eleven (37.9%) with MBI, were recruited and followed-up on average for 33.41 ± 8.24 weeks. Psychiatric symptoms severity and global functioning were assessed, respectively, using the Brief Psychiatric Rating Scale (BPRS) and the Global Assessment of Functioning (GAF) scale. BPRS total score significantly decreased from baseline to follow-up ( P < 0.001, d = 1.33). The presence of MBI had no significant effect on mood and cognitive symptoms improvement. On the contrary, while a significant increase in GAF score was observed in patients without MBI ( P = 0.001, d = 1.01), no significant improvement of global functioning was detected in those with MBI ( P = 0.154, d = 0.34) after 6-month follow-up. The presence of MBI in patients with LLD may negatively affect long-term outcome, slowing or preventing functional improvement.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"305-312"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107591188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

It is ethical to publish successful case reports about patient with treatment-resistant depression. 发表关于耐药抑郁症患者的成功病例报告是合乎道德的。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-01-15 DOI: 10.1097/YIC.0000000000000525

Anne Sauvaget, Samuel Bulteau, Andrew Laurin

引用次数: 0

Mood disorders and somatic comorbidities. 情绪障碍和躯体合并症。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1097/YIC.0000000000000562

Alessandro Serretti

引用次数: 0

Towards a replicable protocol to identify patients with psychiatric disorders at higher risk of developing dementia. 制定一个可复制的方案，以识别罹患痴呆症风险较高的精神障碍患者。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-02-13 DOI: 10.1097/YIC.0000000000000542

Veronika Matuskova, Martin Vyhnalek

引用次数: 0

Manic episode in a patient with pancreatic adenocarcinoma: a case report. 胰腺癌患者躁狂发作1例报告。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2023-09-20 DOI: 10.1097/YIC.0000000000000505

Juan I Mena, Helena Andreu, Anna Giménez-Palomo, Laura Bueno, Eduard Cesari, Óscar De Juan, Iñaki Ochandiano, Luis Olivier, Sergi Salmeron, Eduard Vieta, Isabella Pacchiarotti

{"title":"Manic episode in a patient with pancreatic adenocarcinoma: a case report.","authors":"Juan I Mena, Helena Andreu, Anna Giménez-Palomo, Laura Bueno, Eduard Cesari, Óscar De Juan, Iñaki Ochandiano, Luis Olivier, Sergi Salmeron, Eduard Vieta, Isabella Pacchiarotti","doi":"10.1097/YIC.0000000000000505","DOIUrl":"10.1097/YIC.0000000000000505","url":null,"abstract":"Psychiatric comorbidity is common in cancer patients, emphasizing the need for comprehensive care. While depressive symptoms in pancreatic cancer have been studied, there is limited attention given to manic symptoms. This case report aims to contribute to the knowledge of pancreatic cancer psychiatric comorbidities by describing a case of a patient with stage IV pancreatic cancer who presented a sudden onset manic episode. The patient, a 61-year-old male with stage IV pancreatic cancer, presented at the Emergency Room with abrupt behavioural changes suggestive of a manic episode of 2 weeks of evolution. The patient had been undergoing chemotherapy and short 3-day cycles of corticosteroids for the past 9 months but had been off this treatment for 20 days when the episode began. Acute organic causes were ruled out. The patient was admitted to the psychiatric unit, where organic screening was expanded and treatment with antipsychotics and a mood stabiliser was initiated with subsequent remission of symptoms after 2 weeks. This case shows a manic episode as a rare psychiatric complication in pancreatic cancer. In the literature reviewed, four other similar cases have been observed. Further research is needed to elucidate the underlying pathophysiology and explore possible treatment strategies.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"326-329"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41118742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

l -carnitine adjunct to risperidone for treatment of autism spectrum disorder-associated behaviors: a randomized, double-blind clinical trial. l -肉碱辅助利培酮治疗自闭症谱系障碍相关行为：随机双盲临床试验。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2023-08-07 DOI: 10.1097/YIC.0000000000000496

Mehry Nasiri, Zohal Parmoon, Yalda Farahmand, Ali Moradi, Kimia Farahmand, Kamyar Moradi, Fatemeh A Basti, Mohammad-Reza Mohammadi, Shahin Akhondzadeh

{"title":"l -carnitine adjunct to risperidone for treatment of autism spectrum disorder-associated behaviors: a randomized, double-blind clinical trial.","authors":"Mehry Nasiri, Zohal Parmoon, Yalda Farahmand, Ali Moradi, Kimia Farahmand, Kamyar Moradi, Fatemeh A Basti, Mohammad-Reza Mohammadi, Shahin Akhondzadeh","doi":"10.1097/YIC.0000000000000496","DOIUrl":"10.1097/YIC.0000000000000496","url":null,"abstract":"The present study was designed to evaluate the efficacy and safety of l-carnitine as an adjuvant agent to risperidone in the treatment of autism spectrum disorder (ASD)-associated behaviors. In this study, 68 children with confirmed ASD were randomly allocated to receive either l-carnitine (150 mg/day) or matched placebo in addition to risperidone. We utilized the Aberrant Behavior Checklist-Community Edition scale (ABC-C) and a checklist of potential adverse effects to assess changes in behavioral status and safety profile at weeks 0, 5 and 10 of the trial. The primary outcome was defined as a change in the irritability subscale score. Sixty patients with similar baseline characteristics completed the trial period. Although scores of ABC-C subscales significantly decreased in both groups over the trial period, the combination of l-carnitine and risperidone resulted in more reduction on the irritability and hyperactivity subscales compared to the combination of risperidone and placebo ( P = 0.033 and P < 0.001, respectively). However, changes in lethargy, stereotypic behavior and inappropriate speech subscales were similar between groups. In conclusion, l-carnitine adjuvant to risperidone could improve irritability and hyperactivity features in children with ASD. Results of this study should be considered preliminary and further clinical trials with larger sample sizes and longer follow-up periods are warranted.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"232-239"},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9954147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0